Biotech stocks are undergoing large-scale financing and new therapies are emerging.

In the biomedial industry in the US and European markets in October, there have been many financing activities, totaling over 3 billion USD. This level is back to pre-pandemic levels, really back on track.

Let's start with some key areas. In terms of cancer treatment, several biomedical companies completed financing in October, including Orano Med and Alpha-9, these substantial financing rounds have rekindled the spark in the cancer field. Especially technologies like Orano Med's radiation therapy, which is a direction worth paying attention to in the coming years.

Another area is siRNA drugs, which have recently attracted a lot of investment. Both City Therapeutics and Judo Bio have completed financing rounds of over 100 million USD, making people look forward to more breakthroughs in siRNA in the future. This area of technology has always been a hot spot in biomedical, especially with Arrowhead Pharmaceuticals recent collaboration with major pharmaceutical companies, it feels like this market has the potential to explode in the future.

There are also some cutting-edge technologies, such as Car-T therapy, KCC2 potentiators, macrophage therapy, etc., all of which have received significant funding support. I personally believe that if these new technologies can really be implemented, they will have a breakthrough impact on the treatment of major diseases.

These financing activities demonstrate the market's confidence in the biomedical industry, especially in areas such as cancer treatment, neuroscience, RNAi, etc. The inflow of funds indicates the long-term potential of these areas. However, this also reminds us, the industry competition is very intense, whether these emerging enterprises can succeed is still unknown, and it is worth our continued attention.

Everyone can pay attention to it.

TTF traders.